Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 951-960

  Miao, Raymond ^a   Wei, Wenhui ^a   Baser, Onur ^b,c   Xie, Lin ^b  

^a SANOFI   (France)

^b STATINMED RESEARCH   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clinical outcomes; Diabetes mellitus; Insulin glargine; Premixed insulin; Rapid acting insulin; Treatment persistence; Type 2

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; MEGLITINIDE; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREVALENCE; PROPENSITY SCORE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84884728188     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S49287     Document Type: Article

References (35)

1. Shomali M. Add-on therapies to metformin for type 2 diabetes. Expert Opin Pharmacother. 2011;12(1):47-62.
2. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25(2):330-336.
3. Inzucchi SE, Bergenstal RM, Buse JB, etal. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596.
4. American Diabetes Association (ADA). Standards of medical care in diabetes-2012. Diabetes Care. 2012;35 Suppl 1:S11-S63.
5. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab. 2011;13(11): 1020-1027.
6. Raskin P, Allen E, Hollander P, etal. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260-265.
7. Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med. 2007;18(1):56-62.
8. Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219-230.
9. Peyrot M, Rubin RR, Polonsky WH, Best JH. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Curr Med Res Opin. 2010;26(5):1047-1054.
10. Fritsche A, Larbig M, Owens D, Häring HU. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 2010;12(2):115-123.
11. Holman RR, Thorne KI, Farmer AJ, etal. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716-1730.
12. Holman RR, Farmer AJ, Davies MJ, etal. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18): 1736-1747.
13. Schiel R, Müller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Exp Clin Endocrinol Diabetes. 2008;116(1):58-64.
14. Reaney M, Cypryk K, Tentolouris N, etal. Resource utilisation and clinical data before and after switching between short-acting human insulin and rapid-acting insulin analogues in patients with type 2 diabetes: the SWING study. Diabetes Res Clin Pract. 2012;97(2):231-241.
15. Davies M, Sinnassamy P, Storms F, Gomis R. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract. 2008;79(2):368-375.
16. Lakey WC, Barnard K, Batch BC, Chiswell K, Tasneem A, Green JB. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia. 2013;56(6):1226-1235.
17. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-1892.
18. Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract. 2007;61(12):2009-2018.
19. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol. 2009;8:9.
20. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29(7):e13-e20.
21. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and healthcare costs costs of insulin device (FlexPen®) versus conventional vial/syringe. Adv Ther. 2010;27(2):94-104.
22. National Committee for Quality Assurance. HEDIS 2013. Available from: http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2013.aspx. Accessed July 19, 2013.
23. Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract. 2010;89(2):189-195.
24. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011;17(6): 845-852.
25. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15(3):230-236.
26. Xie L, Wei W, Pan C, Du J, Baser O. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther. 2011;28(11):1000-1011.
27. Baser O, Wei W, Baser E, Xie L. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ. 2011;14(6):673-680.
28. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012;28(3): 439-446.
29. Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care. 2012;35(5):1126-1132.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1): 41-55.
31. Cramer JA, Roy A, Burrell A, etal. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1): 44-47.
32. Polonsky WH, Rosenstock J, Gilmore AS, Wei W, Chaudhs SL, Riddle MC. Patient reported outcomes using twice-daily insulin aspart premixed vs insulin glargine plus 1 prandial insulin glulisine or step-wise addition of glulisine to glargine in type 2 diabetes uncontrolled with oral agents [abstract]. Diabetes. 2011;60 Suppl 1:A616.
33. Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract. 2010;64(12):1609-1618.
34. Agency for Healthcare Research and Quality. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes: Executive Summary. Rockville (MD): AHRQ; 2008. Available from: http://effectivehealthcare.ahrq.gov/ehc/products/18/108/2008_0915InsulinAnaloguesExecSum.pdf. Accessed July 19, 2013.
35. Ilag LL, Kerr L. Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther. 2007;29(6 Pt 1):1254-1270.